Sector News

Novo Holdings invests €86m in bioindustrial company 21st.Bio

January 9, 2022
Life sciences

Novo Holdings has made a €86 million investment in 21st.Bio, a Danish bioindustrial scale-up company.

21st.Bio supports bioindustrial companies with matters such as the upscaling of molecular innovation or large-scale production that can meet market demands and advance the green transition globally.

One core focal area for 21st.Bio is producing proteins and peptides that can be utilised for the food, materials and agricultural industries.

21st.Bio’s technology platform originates from selected parts of Novozymes, which provides a co-exclusive license to 21st.Bio within certain boundaries of applications.

Access to selected parts of Novozymes’ R&D platform and the investment by Novo Holdings will enable the company to expand its capabilities even further.

Thomas Schmidt, co-founder and CEO of 21st.Bio, said: “Many brilliant industrial biotech ideas never succeed, because production challenges result in too high price points for the final product. Hence, a vast number of otherwise great innovations do not make it to a scale at which they are truly relevant for the world”.

He continued: “At 21st.Bio, we can help establish the right technology for producing novel molecules and peptides and hence help innovators successfully make the difficult step from innovation to big business and impact for the planet. We have gained access to a selection of Novozymes’ unique technology platform on commercial terms, which means that a success for 21st.Bio is also a success for Novozymes.”

Søren Møller, managing partner of Novo Seeds at Novo Holdings, will join the company’s board of directors.

By Lauren Ford


comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).